



PROGRESS REPORT FOR IMMEDIATE RELEASE

5 November 2009

Australian healthcare company Stirling Products Limited (ASX:STI) advises that:

Office Purchase

The Company yesterday settled the purchase of its future office headquarters at Ashington House, 16 O'Connell Street, Sydney into which it intends to move early in 2010.

This purchase in central Sydney at the bottom of the market at \$4,000 a square metre will see the company secure a cost base that is, especially going forward, far more favourable than office leasing costs. The acquisition also contributes to a tangible increase to the Company's NTA.

LOIs in Brazil, Mexico and Chile

Finalisation of these relationships has been delayed through the requirement of respective government regulatory product approvals that are currently under review by the Company. Progress of each of the relationships will be further reported as there is material development, however it is expected that each of the Country registration requirements will have been completed during Q1 of 2010.

TB and AIDS Developments

Work is currently underway to finalise commencement of the first of a series of significant trials in South Africa. The Company will advise further as these progress.

Product Launch in North America

The Company's Managing Director will be in the US next week to secure finalisation of senior management appointments for its direct marketing launch of its botanical products.

Final product branding and packaging design is almost complete and the first consignment of product has now been delivered to QPharma for bottling and packaging for the direct marketing initiative.



For further information see www.stirlingproducts.net or contact:

Peter Boonen
Managing Director
Stirling Products Limited
Ph: +61 2 9299 9270
E: peter.boonen@stirlingproducts.net

For all Investor Relations inquiries please contact:

James Moses
Mandate Corporate
Ph: +61 420 991 574
E: james@mandatecorporate.com.au